Is Mankind Pharma overvalued or undervalued?

Jul 04 2025 08:02 AM IST
share
Share Via
As of July 3, 2025, Mankind Pharma is considered expensive with a PE ratio of 49.04 and an EV to EBITDA of 30.79, significantly higher than peers like Sun Pharma and Cipla, while its stock has declined 17.83% year-to-date, indicating it remains overvalued.
As of 3 July 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. Despite this change, the company remains overvalued. Key ratios include a PE ratio of 49.04, an EV to EBITDA of 30.79, and a ROE of 20.02%.

When compared to peers, Mankind Pharma's PE ratio significantly exceeds that of Sun Pharma at 35.23 and Cipla at 23.12, highlighting its relative overvaluation. Additionally, the company's recent stock performance shows a year-to-date decline of 17.83%, contrasting with the Sensex's gain of 6.53%, further reinforcing the notion that Mankind Pharma is overvalued in the current market context.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News